Author's posts
Scientists’ Credibility Crucial To Biopharma’s Reputation
Wouldn’t it be great if interviews with scientists were a weekly feature of major news outlets?
‘Smart Pill’ Schizophrenia Drug Unlikely To Move Payers
Without such data, the ‘smart pill’ is a gimmick that payers will not buy into – literally.
Pharma Money And Physician Prescribing Of Painkillers
If people had concerns that unreasonable payments to physicians were driving up gabapentinoid use, after looking at these facts they should be less concerned that this is the case.
Can A Drug That Delays The Onset Of Type 1 Diabetes Be A Success?
What value is provided by a drug – likely to be a very expensive drug – that
delays the onset of type 1 diabetes for a relatively short period of time?
Azar’s Plan To Tie U.S. Drug Prices To Foreign Ones Will Impact Investments In R&D
However, the Azar proposal is misguided in that, despite his assertions otherwise, enacting it will have a negative effect on pharmaceutical R&D in areas of serious medical need.
What Bluebird Bio Gets Wrong In Pricing For Its $1.8 Million Drug
By enacting the above suggestions, Bluebird Bio can show that it is confident in its product, that it will only get paid if the product works, that it will adjust costs if there is a need for future treatments and that it won’t be opportunistic in taki…
Will The Introduction Of A Third Potent Cholesterol Lowering Drug Expand or Shrink The Market?
Payers still will want to limit access to these drugs given the massive number of patients that could be eligible for treatment.
On The Toxicity Of Humira And Other Rheumatoid Arthritis Drugs
But articles that trumpet 34,000 deaths on important medicines, that denigrate the FDA’s approval process and that suggest these drugs shouldn’t be on the market, don’t really help the discussion.
On The Toxicity Of Humira And Other Rheumatoid Arthritis Drugs
But articles that trumpet 34,000 deaths on important medicines, that denigrate the FDA’s approval process and that suggest these drugs shouldn’t be on the market, don’t really help the discussion.
Merck CEO, Ken Frazier’s Unusual Priority — Science
For a CEO to focus public remarks on science and scientists is rare.
